Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia-Reference-Cited by-同舟云学术

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Published:2023-06-16 Issue:12 Volume:7 Page:2884-2887
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Tam Constantine S.¹^ORCID,Trotman Judith²³^ORCID,Opat Stephen⁴⁵^ORCID,Stern Jennifer C.⁶,Allewelt Heather⁶,By Kunthel⁶,Novotny William⁶,Huang Jane⁶,Tedeschi Alessandra⁷

Affiliation:

1. 1The Alfred Hospital, Monash University, Melbourne, VIC, Australia

2. 2Concord Repatriation General Hospital, Concord, NSW, Australia

3. 3The University of Sydney, Concord, NSW, Australia

4. 4Monash Health, Clayton, VIC, Australia

5. 5Monash University, Clayton, VIC, Australia

6. 6BeiGene, San Mateo, CA

7. 7ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/12/2884/2060141/blooda_adv-2022-008990-main.pdf

Reference12 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis;Else;Br J Haematol,2009

3. National Comprehensive Cancer Network. National Clinical Practice Guidelines in Oncology . Hairy cell leukemia. Version 1.2022. 2022. Accessed 29 March 2022. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf.

4. Patients with relapsed/refractory hairy-cell leukemia;Paillassa;Cancer Rep (Hoboken),2022

5. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL;Tam;Blood,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group;Cancers;2024-06-10

2. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

3. Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia;Blood Advances;2023-11-03